• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Summit Therapeutics Inc. (Amendment)

    2/14/23 4:03:10 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    SC 13G/A 1 polar-smmt123122a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Summit Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    86627T108

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Summit Therapeutics Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    2882 Sand Hill Road, Suite 106

    Menlo Park, CA 94025

    Item 2.(a) Name of Person Filing:

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.01 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    86627T108

     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    Polar Capital LLP

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Based on 201,321,175 shares, which is the total number of shares outstanding as reported in the Issuer's Form 10-Q on November 09, 2022.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person 

    Information for each Subsidiary is incorporated on the respective cover pages..

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           

     

     
    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
    Get the next $SMMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    3/21/2025Overweight
    Cantor Fitzgerald
    3/12/2025$30.00Outperform
    Evercore ISI
    2/28/2025$42.00Buy
    Goldman
    1/8/2025$35.00Buy
    Truist
    12/11/2024$30.00Overweight
    Wells Fargo
    12/6/2024$31.00Buy
    Jefferies
    11/4/2024$32.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Summit Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously

      3/26/25 7:47:33 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Summit Therapeutics

      Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight

      3/21/25 8:11:46 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Summit Therapeutics with a new price target

      Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00

      3/12/25 7:33:36 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Financials

    Live finance-specific insights

    See more
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

      Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and

      4/24/25 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

      Clinical Trial Collaboration with Pfizer Evaluating Ivonescimab in Combination with Several Vedotin ADCs in Unique Solid Tumor Settings; Clinical Trials Expected to Start Mid-2025 Enrollment Completed for Global, Multi-Regional Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Top-Line Data Expected Mid-2025; Received Fast Track Designation from FDA HARMONi-3 Global Phase III Trial Expanded to Include Patients with Squamous and Non-Squamous Histologies Initial Trial Sites Activated for Global Phase III HARMONi-7 Trial in 1L PD-L1 High, Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an updat

      2/24/25 6:05:00 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Summit Therapeutics Inc.

      10-Q - Summit Therapeutics Inc. (0001599298) (Filer)

      5/1/25 4:11:31 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      5/1/25 4:10:10 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Summit Therapeutics Inc.

      DEF 14A - Summit Therapeutics Inc. (0001599298) (Filer)

      4/29/25 4:44:20 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:28:30 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:27:03 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zanganeh Mahkam exercised 805,495 in-the-money shares at a strike of $1.49 and bought $10,350 worth of shares (5,000 units at $2.07) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      12/13/23 5:11:56 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

      Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

      3/17/25 4:24:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

      6/27/24 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

      4/11/24 4:30:00 PM ET
      $ILMN
      $SMMT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      9/13/24 5:54:25 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      3/13/23 4:51:59 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      2/16/23 4:01:07 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

      Interim Analysis of HARMONi-2 Shows an Overall Survival Hazard Ratio of 0.777 Favoring Ivonescimab at 39% Data Maturity, Implying a Potential Numerical 22% Reduction in the Risk of Death Compared to Pembrolizumab Ivonescimab Monotherapy Approved by NMPA in China for Front-Line PD-L1 Positive Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monother

      4/25/25 2:50:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

      Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and

      4/24/25 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:17:22 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by COO and CFO Soni Manmeet Singh

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:13:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:09:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care